Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02554877 · ClinicalTrials.gov registry record · Phase 2
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
A Phase 2 study of Type 2 Diabetes Mellitus, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 206
- Enrollment target
- 20
- Study locations
NCT02554877: Completed Phase 2 study of Type 2 Diabetes Mellitus, sponsored by Pfizer.
NCT02554877 is a Phase 2 study of Type 2 Diabetes Mellitus that has completed, run by Pfizer. The registered enrollment target is 206 participants, below the 2,958-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02554877, a Phase 2 study of Type 2 Diabetes Mellitus, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether PF-06291874 is effective in the treatment T2DM
Primary Outcome
HbA1c was a form of hemoglobin which was measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Baseline was defined as the last pre-dose measurement prior to first double blind dosing for the study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PF-06291874
Study Locations (20)
California
- Anaheim Clinical Trials, LLC - Anaheim
- National Research Institute - Los Angeles
- NRC Research Institute - Orange
- Sierra Clinical Research - Roseville
- Encompass Clinical Research - Spring Valley
- Empire Clinical Research - Upland
- Diablo Clinical Research, Inc - Walnut Creek
Florida
- Clinical Research of South Florida - Coral Gables
- Avail Clinical Research, LLC - DeLand
- Suncoast Research Group, Llc - Miami
- QPS-MRA, LLC (Miami Research Associates) - South Miami
- Palm Beach Research Center - West Palm Beach
New Jersey
- Comprehensive Clinical Research - Berlin
- Clinilabs Inc. - Eatontown
Georgia
- WR-Mount Vernon Clinical Research, LLC - Sandy Springs
Hawaii
- East-West Medical Research Institute - Honolulu
Indiana
- Midwest Institute for Clinical Research - Indianapolis
Louisiana
- Crescent City Clinical Research Center, LLC - Metairie
Missouri
- St. Louis Clinical Trials, LC - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
What the finished NCT02554877 record still lists
NCT02554877 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, below the 2,958-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02554877 names 20 study sites across 9 states, led by California, Florida, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02554877 about?
NCT02554877 is a clinical study titled "A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin". The purpose of this study is to determine whether PF-06291874 is effective in the treatment T2DM
What is the current status of trial NCT02554877?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 206 participants. The study started on 2015-10. Estimated completion is 2016-08.
What conditions does trial NCT02554877 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT02554877?
The interventions under investigation include: Placebo (DRUG), PF-06291874 (DRUG).
Who is sponsoring clinical trial NCT02554877?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02554877 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Hawaii, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02554877's enrollment target sits among peer trials
206 38th of 130 higher than 93 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Regulation of Endogenous Glucose Production by Central KATP Channels
RECRUITING · Phase 2
-
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
COMPLETED · Phase 2
-
The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
COMPLETED · Phase 2
-
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia